Wikipedia -WSS

Wikipedia

author：comprehensive 2025-09-27 23:01:10 - browse：3118

Chief executive officer of Sanofi Paul Hudson, wearing glasses, speaks into a mic — pharma coverage from STAT — Sanofi CEO Paul Hudson Carolyn Kaster/AP

LONDON — Sanofi CEO Paul Hudson on Wednesday defended his company’s recent moves to abandon future profit guidance and up its investment in its own research programs, arguing that the dramatically negative market response didn’t reflect the potential rewards that could stem from the plan.

“Would I have liked the stock market reaction to be more generous? Of course,” Hudson said at a Financial Times event in London. “But this is a long-term game, and if you’re trying to deliver long-term value, you try not to make too many short-term decisions.”

Sanofi unveiled its R&D plans late last month as it announced its third-quarter performance and said that it was spinning out its consumer health division. As the company said it was going to spend more money on research, it also withdrew earnings outlooks for 2025. Company executives have argued that this was the moment — when Sanofi has a strong pipeline and isn’t facing patent expirations for years — to increase its R&D resources, even at the expense of short-term profits.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Supreme Court strikes down use of affirmative action
Next article： Goldman Sachs launches $650M fund for life science investments

hotspot

explore

WSS

Federal weight loss drug coverage is 30 years out of date

Antibiotic resistance and the global rise in human conflict

The biotech scorecard for Q1: 17 stock

U.K. sequencing study surfaces new findings about tumor DNA

When waiting feels immoral: Empathy in the emergency department

Ahead of JPM, here's who's profiting most in health care

hotspot

Wikipedia

hotspot

At least 13 dead in Texas as scorching temps continue

GSK Flovent asthma inhalers replaced by authorized generics

Hepatitis C has a cure — but many Americans still lack access to it

Insitro, AI biotech unicorn, brings cash, new research to JPM 2024

Virginia high school admissions case could be legal follow

Readout Newsletter: Allogene's pivot, Illumina exec to lead Delfi

The high cost of giving birth even with insurance

Susan Tousi leaves Illumina to head cancer liquid biopsy startup

Alkermes shareholders re

Biotech startup Celsius cuts 75% of staff ahead of first trial start

Wikipedia

Chris Christie meets with Zelenskyy during Ukraine trip

The cancer stories no one wants to hear

A single drug, study failures leave Anavex with nothing but cash

Florida officials tell state schools to teach AP Psychology 'in its entirety'

Morgan Health, with ambitious aims, wants you to know it’s still here

Chronically ill young patients struggle to find fertility info

hotspot

explore

explore

knowledge